Tumor necrosis factor receptor superfamily member 1A intracellular signaling complex (TNFR1-SC)

The Tumor necrosis factor receptor superfamily member 1A (TNFR1) intracellular signaling complex is a dynamic multi-protein assembly that forms upon the binding of Tumor Necrosis Factor-alpha (TNF-alpha) to the TNFR1 receptor (UniProt P19438) [1]. This complex is a critical mediator of the immune response, governing the balance between cell survival, inflammation, and programmed cell death [2]. Upon ligand binding, the receptor recruits adaptor proteins such as TRADD, RIPK1, and TRAF2 to form "Complex I" at the plasma membrane, which activates the NF-kappaB and MAPK pathways to promote pro-inflammatory gene expression and survival [2,3]. Under certain conditions, this assembly transitions into secondary cytoplasmic complexes, such as "Complex II" (leading to apoptosis) or the "Necrosome" (leading to necroptosis) [3]. Dysregulation of these signaling events is implicated in a wide range of pathologies, including rheumatoid arthritis, inflammatory bowel disease, and various cancers [4]. Pharmacological intervention typically involves neutralizing the TNF-alpha ligand to prevent complex formation or using small molecules to inhibit specific intracellular components like RIPK1 to modulate downstream signaling outcomes [4].

Other names

TNFR1 signaling complexTNFRSF1A signaling complexComplex IComplex IINecrosomeTNF-R1 signaling complex

Neutralization of TNF-alpha to prevent receptor binding and complex assembly; inhibition of intracellular kinases (e.g., RIPK1) or E3 ligases (e.g., IAPs) within the complex to modulate downstream signaling.